uniQure/$QURE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About uniQure
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Ticker
$QURE
Sector
Primary listing
Employees
209
Headquarters
Website
uniQure Metrics
BasicAdvanced
$1.9B
-
-$4.35
-
-
Price and volume
Market cap
$1.9B
52-week high
$71.50
52-week low
$5.50
Average daily volume
4.1M
Financial strength
Current ratio
7.117
Quick ratio
6.937
Long term debt to equity
230.714
Total debt to equity
232.425
Interest coverage (TTM)
-2.82%
Profitability
EBITDA (TTM)
-159.66
Gross margin (TTM)
-140.89%
Net profit margin (TTM)
-1,492.90%
Operating margin (TTM)
-1,116.15%
Effective tax rate (TTM)
-4.63%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-14.32%
Return on equity (TTM)
-165.27%
Valuation
Price to revenue (TTM)
104.263
Price to book
6.5
Price to tangible book (TTM)
11.5
Price to free cash flow (TTM)
-10.692
Free cash flow yield (TTM)
-9.35%
Free cash flow per share (TTM)
-2.838
Growth
Revenue change (TTM)
-44.90%
Earnings per share change (TTM)
-12.17%
3-year revenue growth (CAGR)
-36.47%
10-year revenue growth (CAGR)
6.22%
3-year earnings per share growth (CAGR)
17.33%
10-year earnings per share growth (CAGR)
1.03%
What the Analysts think about uniQure
Analyst ratings (Buy, Hold, Sell) for uniQure stock.
uniQure Financial Performance
Revenues and expenses
uniQure Earnings Performance
Company profitability
uniQure News
AllArticlesVideos
uniQURE N.V. Investigation: Investors Encouraged to Contact Kirby McInerney LLP
Business Wire3 days ago
NASDAQ: QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
Business Wire1 week ago
UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data
Benzinga2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for uniQure stock?
uniQure (QURE) has a market cap of $1.9B as of November 15, 2025.
What is the P/E ratio for uniQure stock?
The price to earnings (P/E) ratio for uniQure (QURE) stock is 0 as of November 15, 2025.
Does uniQure stock pay dividends?
No, uniQure (QURE) stock does not pay dividends to its shareholders as of November 15, 2025.
When is the next uniQure dividend payment date?
uniQure (QURE) stock does not pay dividends to its shareholders.
What is the beta indicator for uniQure?
uniQure (QURE) does not currently have a Beta indicator.